CASI

2.125

0.71% 0.015

Dopo l'orario di chiusura: 2.13 0.005 +0.24%

Casi Pharmaceuticals Inc (CASI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.11

Aprire:

$1.9

Volume 24 ore:

35,701

Relative Volume:

2.11

Capitalizzazione di mercato:

$32.92M

Reddito:

$22.06M

Utile/perdita netta:

$-30.94M

Rapporto P/E:

-0.9487

EPS:

-2.24

Flusso di cassa netto:

$-26.70M

1 W Prestazione:

-3.41%

1M Prestazione:

-6.39%

6M Prestazione:

-60.97%

1 anno Prestazione:

-35.02%

Intervallo 1D:

$1.90

$2.24

Intervallo di 1 settimana:

$1.90

$2.42

Portata 52W:

$1.90

$7.67

Casi Pharmaceuticals Inc Stock (CASI) Company Profile

Nome

Casi Pharmaceuticals Inc

Settore

Healthcare (1174)

Industria

Biotechnology (678)

Telefono

Indirizzo

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-14

Ultimi documenti SEC

CASI's Discussions on Twitter

Confronta CASI con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CASI Casi Pharmaceuticals Inc	2.125	32.92M	22.06M	-30.94M	-26.70M	-2.24
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	68.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Casi Pharmaceuticals Inc Stock (CASI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-05-18	Iniziato	BTIG Research	Buy
2021-04-26	Iniziato	Mizuho	Buy
2020-10-23	Iniziato	Oppenheimer	Outperform
2016-09-22	Iniziato	Maxim Group	Buy
2015-10-29	Ripresa	H.C. Wainwright	Buy
2015-06-23	Iniziato	H.C. Wainwright	Buy

Mostra tutto

Casi Pharmaceuticals Inc Borsa (CASI) Ultime notizie

04:59 AM

CASI Pharmaceuticals Acquires Precision Autoimmune Therapeutics - TipRanks

04:59 AM

04:48 AM

Casi Pharmaceuticals Signs Agreement To Acquire Equity Interests In Precision Autoimmune Therapeutics - MarketScreener

04:48 AM

04:15 AM

CASI Pharma stock hits 52-week low at $1.9 amid market challenges - Investing.com India

04:15 AM

03:30 AM

CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely - Asianet Newsable

03:30 AM

08:58 AM

CASI Pharmaceuticals receives buyout proposal from CEO - Investing.com India

08:58 AM

08:52 AM

CASI Pharmaceuticals Receives Updated Acquisition Proposal for China Operations - TipRanks

08:52 AM

08:05 AM

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company - ACCESS Newswire

08:05 AM

08:00 AM

CASI Pharma's CEO Makes Strategic $20M Bid for Entire China BusinessKey Pipeline Assets Included - Stock Titan

08:00 AM

Apr 02, 2025

CASI Pharmaceuticals Full Year 2024 Earnings: US$2.56 loss per share (vs US$2.02 loss in FY 2023) - Yahoo Finance

Apr 02, 2025

Apr 01, 2025

Short Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Declines By 15.0% - Defense World

Apr 01, 2025

Mar 31, 2025

CASI Pharmaceuticals Reports 2024 Financial Results and Strategic Developments - TipRanks

Mar 31, 2025

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results - ACCESS Newswire

Mar 31, 2025

CASI Delivers Record Q4 Growth: FDA Clearance Powers Next-Gen Treatment Pipeline - Stock Titan

Mar 31, 2025

Mar 21, 2025

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shares Lagging The Industry But So Is The Business - Simply Wall St

Mar 21, 2025

Mar 19, 2025

CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by StockNews.com - Defense World

Mar 19, 2025

Mar 11, 2025

CASI Pharma stock hits 52-week low at $2.04 amid market challenges - Investing.com

Mar 11, 2025

StockNews.com Initiates Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World

Mar 11, 2025

Mar 03, 2025

StockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World

Mar 03, 2025

Feb 27, 2025

CASI Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

Feb 15, 2025

CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated at StockNews.com - Defense World

Feb 15, 2025

Feb 10, 2025

Hypoxia Treatment Market to Witness Substantial Growth by 2031 | - openPR

Feb 10, 2025

CASI Pharmaceuticals (NASDAQ:CASI) Research Coverage Started at StockNews.com - Defense World

Feb 10, 2025

Multiple Myeloma Clinical and Non-Clinical Studies, Key - openPR

Feb 10, 2025

CASI Pharmaceuticals Secures Interim Relief in Juventas Dispute - TipRanks

Feb 10, 2025

Feb 03, 2025

Critical Comparison: Biora Therapeutics (NASDAQ:BIOR) versus CASI Pharmaceuticals (NASDAQ:CASI) - Defense World

Feb 03, 2025

Jan 31, 2025

Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World

Jan 31, 2025

Jan 30, 2025

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) Secures EU Patent for FHAB Platform Technology - Defense World

Jan 30, 2025

CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com - Defense World

Jan 30, 2025

Jan 27, 2025

Multiple Myeloma Pipeline 2024: FDA Approvals, Therapies, - openPR

Jan 27, 2025

Jan 26, 2025

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - ACCESS Newswire

Jan 26, 2025

Jan 24, 2025

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - ACCESS Newswire

Jan 24, 2025

Jan 21, 2025

CASI Pharmaceuticals Faces Asset Freezing Amid Arbitration Dispute - TipRanks

Jan 21, 2025

Jan 19, 2025

Assenagon Asset Management S.A. Increases Stock Holdings in Premier, Inc. (NASDAQ:PINC) - Defense World

Jan 19, 2025

Jan 08, 2025

Can this 10.8% yield from a FTSE 250 share last? - Yahoo Finance UK

Jan 08, 2025

Jan 06, 2025

CASI Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Marketscreener.com

Jan 06, 2025

CASI Pharmaceuticals Launches Pivotal Phase 1/2 Trial for Novel ITP Treatment CID-103 - StockTitan

Jan 06, 2025

Dec 31, 2024

Major 2024 licensing deals confirm Asia’s ascent from copier to innovator - BioWorld Online

Dec 31, 2024

Dec 26, 2024

CASI Pharmaceuticals, Inc. Announces Clinical Hold of CID-103 for Antibody Mediated Rejection of Kidney Transplant - Marketscreener.com

Dec 26, 2024

CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA - TipRanks

Dec 26, 2024

Dec 19, 2024

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - The Eastern Progress Online

Dec 19, 2024

Switch Therapeutics Appoints David M. Holtzman, M.D., to Its Scientific Advisory Board and Announces Its First Development Candidate, CASi-APOE, a Liver-Sparing APOE RNAi Therapy - BioSpace

Dec 03, 2024

Nov 26, 2024

The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34% - Simply Wall St

Nov 26, 2024

Nov 22, 2024

CASI Pharmaceuticals Insider Ups Holding By 65% During Year - Simply Wall St

Nov 22, 2024

Nov 17, 2024

CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q3 Revenue $7.8M - Marketscreener.com

Nov 15, 2024

CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 15, 2024

CASI Pharma Q3 Revenue Jumps 96% QoQ to $7.8M Despite Wider Losses, Advances Pipeline | CASI Stock News - StockTitan

Nov 15, 2024

Nov 12, 2024